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Background. There are little comparative data on catheter ablation of paroxysmal atrial fibrillation (AF) using the contact force
radiofrequency (CF-RF) catheter versus the second-generation cryoballoon (CB2). Methods and results. This is a single center,
retrospective, nonrandomized study of 98 patients with symptomatic, drug-refractory paroxysmal AF who underwent their first
PVI ablation using either the CB2 (𝑛 = 40) or CF-RF (𝑛 = 58).Themean age was 60 years with 63%men, a mean LA size of 42mm.
The procedure duration (74±17 versus 120±49minutes 𝑝 < 0.05) was shorter for CB2 group; the fluoroscopy time (14±17 versus
16 ± 5 minutes, 𝑝 = 0.45) was similar. Complete PVI was achieved in 96% of patients with RF-CF and 98% with CB2. Phrenic
nerve palsies (2 transient and 1 persistent) occurred exclusively in the CB2 group and 1 severe, nonlethal complication (pericardial
tamponade) occurred in the CF-RF group. At 24-month follow-up, the success rate, defined as freedom from AF/atrial tachycardia
(AT) after a single procedure without antiarrhythmic drug, was comparable in CF-RF group and CB2 group (65.5% versus 67%,
resp., log rank 𝑝 = 0.54).Conclusion. Both the CB2 and the RF-CF ablation appeared safe; the success rate at 2 years was comparable
between both technologies.
1. Introduction
In transcatheter ablation of pulmonary veins (PVs), pul-
monary vein isolation (PVI) has been established as an effec-
tive therapeutic option for patients with symptomatic drug-
refractory paroxysmal atrial fibrillation (AF). PVI can be
successfully achieved with different energy sources; radiofre-
quency ablation (RF) and cryoballoon (CB) ablation are
the most frequently used technologies [1–6]. RF ablation
by means of a focal-tip catheter in combination with a 3D
mapping system is still the standard technique performed
worldwide. With continuous improvements in catheter tech-
nology, such as contact force radiofrequency (CF-RF), addi-
tional clinical benefit during PVI is reported when compared
to non-CF technology in recent prospective, nonrandomized
trials. Marijon et al. reported a potential benefit of real-time
contact force sensing technology (compared to conventional
irrigated radiofrequency ablation catheter), in reducing AF
recurrence during the first year after PVI in 60 patients,
Jarman et al. reported the results of a total of 600 ablation
procedures (200 using CF-RF), the mean follow-up was 12
months, and the use of force sensing catheters independently
predicted clinical success in paroxysmal AF patients [7, 8].
Operator experience is a determinant of outcome after PVI
even in high-volume centres [9]. In recent years, the use
of novel balloon based technologies such as cryoballoon
ablation has emerged as an alternative approach to point-
by-point technology [5, 6]. CB technology might offer more
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reproducible and standardizable procedures by simplifying
the ablation itself.There are certain practical advantages, such
as reduced pain during ablation, improved catheter stability
due to catheter-tissue adhesion, and ability to rapidly create
circumferential lesions. Although it is clear that the patients
benefit more from an experienced cryoballoon operator,
Mikhaylov et al. showed that, in low-volume centres, where
operators have experience in simple ablation procedures, CB
is a safe procedure with success rates comparable to those
obtained in higher-volume AF centres. This underlines that
CB has a fast and reproducible learning curve in both high-
and low-volumeAF ablation centres [10].Thefirst-generation
CB was compared to standard RF ablation by Mugnai et
al., who reported similar AF recurrence and AF episode
burden after pulmonary vein isolation using conventional
irrigated radiofrequency energy versus the first-generation
cryoablation. Freedom from AF was reached in 63.5% of
patients treated with cryothermia and 57.3% of patients
treated with RF at 23-month follow-up [11]. The prospective
FreezeAF trial demonstrated noninferiority of CB ablation
versus RF ablation for treating patients with paroxysmal AF.
The primary endpoint (freedom from atrial arrhythmia) at 12
months was achieved by 70.7% with RF and 73.6% with CB
(multiple procedure success), including 31 redo procedures in
each group (19.5% of RF versus 19.9% of CB; 𝑝 = 0.933) [12].
Recently, the second-generationCB (CB2) has been intro-
duced featuring homogeneous cooling of the entire frontal
surface with increased refrigerant flow [13]. Significantly
improved clinical outcome was demonstrated by Fu¨rnkranz
et al. (83.6% versus 63.9% of arrhythmia-free survival) upon
using the second-generation CB after a single procedure
without AAD therapy after 1 year when compared to the
first-generation CB [14]. A recently published multicentre,
retrospective study of more than 1100 patients suggests that
freedom from atrial fibrillation following PVI using the
second-generation CB is superior to open irrigated, non-
force sensing RF based ablation at 12 months following a
single procedure [15].
To the best of our knowledge, published data on com-
parison of medium- and long-term results between new
generation CB and conventional manual CF-RF ablation are
limited.The aim of this study was to compare the efficacy and
safety of the new cryoballoon ablation (CB2) with the CF-RF
approach in the treatment of paroxysmal AF.
2. Methods
This was a nonrandomized, retrospective, single centre study.
From September 2012 to December 2013, 98 patients with
drug resistant paroxysmal atrial fibrillation (defined as self-
terminated, documented episodes lasting <7 days) who
underwent initial PVI using either radiofrequency energy
with contact force sensing ablation catheter (ThermoCool
SmartTouch, BiosenseWebster Inc., Diamond Bar, CA, USA;
𝑛 = 58) or the second-generation cryoballoon (Arctic Front
Advance, Medtronic, Minneapolis, MN, USA; 𝑛 = 40) were
enrolled. Written informed consent was obtained from all
the patients. Before the procedure, all patients underwent a
2-dimensional transthoracic echocardiography to assess left
ventricular ejection fraction and atrial dimensions and to rule
out any structural and/or valvular disease. A transesophageal
echocardiography was performed the day before ablation to
analyze left atrial (LA) and PV anatomy and to rule out
intracardiac thrombus formation. Antiarrhythmic medica-
tions were not stopped before the procedure.
All patients received anticoagulation therapy during the 4
weeks before and for at least 3 months after the index proce-
dure. Periprocedurally, administration of the anticoagulation
therapy was uninterrupted, regardless of the selected drug.
RF ablation instances were performed as follows.
Two nonsteerable long sheaths (St. Jude Medical, St
Paul, MN, USA) were introduced into LA using a double
transseptal puncture technique. An initial intravenous bolus
of heparin (100 IU/kg) was followed by extra boluses to
maintain an activated clotting time (ACT) > 300 s. An
electroanatomicmap of the LAwas performed using CARTO
system (BiosenseWebster Inc., Diamond Bar, CA, USA) with
a circumferential mapping catheter (LassoNav, Biosense
Webster Inc., Diamond Bar, CA, USA). Antral PVI was
performed with open irrigated tip 3.5mm force sensing abla-
tion catheter (Navistar Thermocool SmartTouch, Biosense
Webster Inc., Diamond Bar, CA, USA) in a power-controlled
mode with a power limit of 35W and at a maximum tem-
perature of 48∘C. Power was reduced to 25W during ablation
of LA posterior wall to prevent esophageal injury. The PVs
were isolated by a circumferential lesion set. The endpoint
was elimination of local bipolar electrogram during ablation
with 20–40 s lesions. The VisiTagmodule of CARTO 3 had
been used in patients since January 2013; the settings during
LA ablationwas amodification of the settings reported by Lin
et al. [16]:
(i) A minimum time of 20 seconds.
(ii) A maximum range of 4mm.
(iii) A force over time of 50%.
(iv) A minimum force of 6 g.
ThedesiredminimumCFwas 10 g for lesion formation; upper
limit defined was 50 g force to avoid perforation.
CB ablation instances were performed as follows.
A single transseptal puncture was achieved under fluo-
roscopic guidance. After gaining the LA access, a 100UI/kg
heparin intravenous bolus was given, as well as extra boluses
tomaintain ACT > 300 s. A 0.32 Fr exchange wire (Emerald
Cordis, Johnson and Johnson, Diamond Bar, CA, USA) was
advanced in the left superior PV and a steerable 15 Fr over-
the-wire sheath (FlexCathAdvance,Medtronic,Minneapo-
lis, MN, USA) was positioned in the left atrium. A circular
mapping catheter (Achieve, Medtronic, Minneapolis, MN,
USA) together with a second-generation 28mm double-
walled CB (Arctic Front Advance, Medtronic, Minneapolis,
MN, USA) was then advanced and positioned in the PV
ostiumof each vein. Vessel occlusionwas evaluated according
to a semiquantitative grading ranging from grade 0 (very
poor occlusion) to grade 4 (perfect occlusion) after dye
injection; optimal vessel occlusion was deemed as total
contrast retention with no backflow in the atrium. For each
vein, cryoablation consisted of ≥1 applications lasting 4min.
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Phrenic nerve function was monitored during right superior
vein cryoablation by fluoroscopic assessment of diaphragm
movement during spontaneous breathing.
All procedures were performed under deep sedation
utilizing fractionated intravenous bolus of midazolam and
fentanyl or continuous infusion of propofol with preservation
of spontaneous breathing and continuous monitoring of
oxygen saturation.
PV isolation was guided by circular mapping catheter
(LassoNav, Biosense Webster Inc., Diamond Bar, CA, USA,
and Achieve, Medtronic, Minneapolis, MN, USA) in both
groups. Once entrance block was confirmed, pacing from
all the bipoles on the circular mapping catheter was used
to assess exit block by using a pacing stimulus of 10mA
at 2ms. Evidence for PV capture without conduction to
LA was necessary to prove exit block. The procedures were
stopped immediately after initial isolation; adenosine was not
administered.
Postprocedural anticoagulation was started after sheath
removal with low molecular weight heparin, or NOAC.
Anticoagulation after the procedure was continued for at
least three months or longer depending on the individual
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-VASc score. Antiarrhythmic drugswere continued
for 3 months after ablation and then were stopped.
2.1. Patient-Follow-Up. Clinical follow-up consisted of physi-
cal examinations, 12-lead ECG, and 24-hourHolter recording
performed at 3, 6, and 12 months after ablation and every 6
months after the first year. At 9, 15, and 21 months, patients
were asked about their AF symptoms with standardized
questionnaires by telephone. We directed patients to check
their pulse rate and rhythm at least once a day and to visit the
outpatient clinic if they experienced relapse of AF.
A blanking period of 3 months was considered for the
study. All documented episodes of atrial tachyarrhythmias
lasting 30 seconds and any symptoms suggesting AF were
considered as recurrence. Success rate was defined as the
percentage of patients who did not have any documented AF
episode or any symptoms suggesting AF recurrence after the
blanking period within the follow-up period.
2.2. Statistical Analysis. Continuous measures are expressed
as the mean value ± standard deviation and were analyzed
with the two-sided 𝑡-test after testing for normal distribution
with the method of Kolmogorov and Smirnov. 𝜒2 test was
used for between-groups comparison. Kaplan-Meier event-
free survival analysis was conducted to assess the cumulative
freedom from recurrence. A 𝑝 value <0.05 was considered
statistically significant.
3. Results
Starting in September 2012, a total of 98 patients were
included in the study.
Baseline characteristics are shown in Table 1.
Procedure time (from venous puncture to removal of
sheaths) was significantly shorter in the CB2 group (74 ±
17 minutes versus 120 ± 49, 𝑝 < 0.05); fluoroscopy time
was similar in both groups (14 ± 17 versus 16 ± 5 minutes,
𝑝 = 0.45). Complete PVI was achieved in 98% (39 of 40)
of cryoballoon-treated patients and in 96% (56 of 58) of RF-
treated patients. The 28mm cryoballoon was used during
all procedures without touch-ups. Three left common PVs
(LCPVs) were identified in the 40 patients.Themean number
of CB applications per PV was 1.5 ± 0.8 for the LSPV, 1.3 ± 0.6
for the LIPV, 1.5 ± 0.8 for the RSPV, 1.7 ± 0.9 for the RIPV, and
2.0 ± 1.3 for the LCPV, respectively.
The minimum balloon temperatures (as marker of
balloon-tissue contact) measured were lower in the inferior
PVs: LSPV: −49.5 ± 6∘C versus LIPV: −44.6 ± 7∘C (𝑝 < 0.05)
and RSPV: −50 ± 7∘C versus RIPV: −41 ± 10∘C (𝑝 < 0.001),
respectively.
Real-time catheter-tissue contact force and force time
integral (FTI) were continuously monitored in 51 out of 58
CF-RF patients.
Significantly lower FTI values were detected on the
anterior and inferior aspects of the left pulmonary veins and
the posteroinferior region of the right inferior pulmonary
vein as compared to the other PV regions using nonsteerable
sheaths (Figure 1).
All patients completed the 12-month and the extended 24-
month follow-up. At 1 year, 77.5% (45/58) in the CF-RF group
and 80% (32/40) in the CB2 group were free from recurrent
AF/AT, while at 24months 65.6% (38/58) in the CF-RF group
and 67.5% (27/40) in the CB2 group off AAD remained in
sinus rhythm without statistical significance (Figure 2).
After index PVI, the previously ineffective AAD was
started in all patients experiencing recurrence. A total of 22
patients unresponsive to AAD (15 pts from CF-RF and 7 pts
from CB group) suffering from AF recurrence underwent a
repeat ablation 13.3 ± 7.8 months after initial PVI. All repeat
procedures were performed by themeans of RF energy. In the
CF-RF group, among 60 PVs, 37 (61%) showed conduction
gaps in 15 patients (2.5 per patient), whereas in theCB2 group,
among 28 veins, 10 (35%) showed a PV reconnection in 6
patients (1.4 per patient) (𝑝 = 0.01). In one CB2 patient, all
the PVs were isolated despite of documented symptomatic
paroxysmal atrial fibrillation episodes; non-PV foci were
ablated.
Reconnection rates per vein in the CF-RF group were
as follows: LSPV: 53% (8/15), LIPV: 66% (10/15), RSPV: 40%
(6/15), and RIPV: 87% (13/15).
The inferior pulmonary veins (the left and right inferior
PVs) were frequently reconnected in the CB2 group (86%
12/14 veins), while conduction gaps could be documented in
the right and left superior PV only in one patient.
Procedural complication rate was low. One pericardial
tamponade treated by pericardiocentesis in the CF-RF group
was detected, with 3 phrenic nerve palsies in the CB2 group,
two resolved completely before hospital discharge, and the
third also did resolve after 12 months.
4. Discussion
As far as we know, these are the first published data with the
longest follow-up to compare the feasibility and efficacy of the
second-generation cryoballoon ablation in circumferential
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Table 1: Patients’ baseline characteristics (LA: left atrial, NOACs: novel oral anticoagulants).
Patients (n) RG group (58) CB group (40) p value
Age (years) 61 ± 9 59 ± 10 ns
Female gender n (%) 20 (34) 13 (32.5) ns
LA size (mm) 42.1 ± 4.6 41.3 ± 4 ns
Hypertension (%) 30 (51%) 17 (42.5) ns
Type II diabetes (%) 3 (5.1) 2 (5) ns
Coronary artery disease (%) 7 (12) 5 (12.5) ns
Medication prior to ablation
Beta blockers (%) 55 (95) 40 (100) ns
Propafenone (%) 24 (41) 12 (30) ns
Sotalol (%) 2 (3) 0 (0) ns
Amiodarone (%) 2 (3) 1 (2.5) ns
Acenocoumarol (%) 40 (69) 29 (72.5) ns
NOACs (%) 5 (8.6) 4 (10) ns
Right PVs Left PVs
Anterior Anterior
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Figure 1: Distribution of mean force time integral (FTI) values (gs) per PV-quadrants in the CF-RF group.
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Figure 2: Kaplan-Meier estimation of the time to AF recurrence after single ablation in the CF-RF and CB ablation groups (CB group: solid
line; RF group: dotted line).
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PV isolation with contact force sensing RF ablation in
paroxysmal atrial fibrillation after 2 years.Though the results
of this single centre, retrospective study should be interpreted
carefully, several findings are noteworthy.
First, in our study no differences of medium- and long-
term success rates were found between both CF-RF and
CB2 groups (76.5% versus 81% at 12 months and 65.5% and
67.5% at 24 months). Our results are similar to those of
the SMART-AF trial, where the 12-month success rate was
74% with CF-RF catheters [17] while several studies reported
80% or even higher clinical success with the new generation
cryoballoon at 1 year [14, 18]. In the recently published FIRE
and ICE multicentre randomized study where the mean
duration of follow-up was 1.5 years, the reported recurrence
rates were 34.6% and 35.9% in the cryoballoon and in the
radiofrequency group. Although the representation of the
most advanced generation catheters was not equal in this
study (first-generation CB (24%) and CB2 (76%) in the CB
group and non-CF-RF (76%) and CF-RF (24%) in the RF
group), no significant difference was found between the
catheters used in terms of efficacy and safety [19].
The use of nonsteerable long sheath might have influ-
enced the success rate in the CF-RF group in our study.
The use of steerable sheath theoretically would improve the
outcome of CF-RF ablation; these devices were designed to
improve access to and contact with ablation target sites. One
prospective, randomized, controlled study demonstrates that
AF catheter ablation using a steerable transseptal sheath is
associated with a significantly better rhythm control com-
pared with an ablation with a nonsteerable sheath. Single
procedure outcome has improved by 20% [20].
The improvements in cryoballoon cooling homogeneity
found in Arctic Front Advance may address some issues
that impeded long-term success of cryoballoon ablation as
reported by several authors [13–15]. In fact, the CB2 might
achieve significantly lower temperatures and faster isolation
times in comparison with the first-generation device [14].
We aimed for single 4-min-duration freeze-thaw cycles at all
PVs without bonus freeze. This concept has been applied by
other operators using the CB2 [21], and even a recent report
on acute procedural outcomes and short-term follow-up of
CB2 ablation with 3-min duration freeze-thaw cycles showed
excellent results [22].
In our study, CB2 ablation was associated with signifi-
cantly shorter procedure (from venous puncture to removal
of sheaths) time (74 ± 17 minutes versus 120 ± 49, 𝑝 <
0.05), as compared to CF-RF, which is in line with most
of the published comparative studies (RF versus CB) in the
literature [11, 19].
Despite AF ablation using cryoenergy and RF ablation
with real-time contact force monitoring evolved dramatic
improvements, arrhythmic recurrences after the index proce-
dure remain relatively frequent and in most cases are related
to PV reconnections [23, 24].
Ciconte et al. reported a significantly higher rate of late
PV reconnection following CF-RF ablation when compared
with CB2 ablation 9.8–11.7 months after the index procedure.
The reported rate of PV reconnection (20.4% versus 36.1%; 1.2
versus 1.8 per patient) and anatomical reconnection pattern
around the pulmonary veins were different in the two groups
[24]. We found higher reconnection rates both in the CF-RF
group (61%, 2.5 per patient) and in the CB2 group (35%, 1.4
per patient) (𝑝 = 0.01).
In the CB2 group, dominantly the inferior veins recon-
nected, superior PV reconnection was detected only in 1
out of 7 patients. The explanation is probably the straight
orientation of the cryoballoon catheter towards the superior
vein antrum, which allows better vessel occlusion, lower
nadir temperature, and better tissue-balloon contact, while,
in case of difficult occlusion of the inferior PVs, a pull-down
technique is needed in order to obtain electrical isolation.
Cryoballoon temperatures give reliable information about
balloon-tissue contact. Minimum temperature achieved dur-
ing inferior vein cryoablation was significantly decreased in
our study as compared with those measured in the superior
PVs.
Although acute isolation can be successfully achieved
with CF-RF, late PV reconduction is found in at least one vein
during redo procedures [24]. EFFICAS I study has recently
showed that 65% of patients following CF-RF procedure
experienced a reconnection in at least 1 PV 3 months after
ablation, which was related to lower CF values. We found
2.5 nonisolated PVs per patient; the predominant site of PV
reconnection was the anterior-inferior segments of the left
PVs, as well as the inferior and inferoposterior part of the
RIPV. The use of nonsteerable sheath and the longer follow-
up (13.3 ± 7.8 months) may be responsible for the different
reconnection rates observed in the present study. The lowest
FTI values on all left anterior positions are in line with the
findings reported in EFFICAS I study, where a deflectable
sheath was used in 46% of the patients. The extended use of
steerable sheathmay result in higher CF values and lower late
conduction gaps upon targeting these PV segments.
4.1. Periprocedural Complications. No death and no stroke or
TIA occurred in our study while pericardial tamponade in
one patient (1.7%) in the CF-RF group and phrenic nerve
palsy in 3 patients in theCB2 group (7.5%)were observed.The
tamponade was successfully treated by pericardial drainage.
Luckily, 2 phrenic nerve palsies recovered spontaneously
before hospital discharge, and one recovered after 1 year
follow-up; our results were similar to previously published
data [19].
5. Conclusion
Both the second-generation cryoballoon and the contact
force RF ablation appeared safe. PVI for paroxysmal AF
is faster with CB and results in a similar single procedure
success rate at 2-year follow-up as the conventional point-by-
point CF-RF.
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